

DLA PIPER RUDNICK GRAY CARY US LLP
INTELLECTUAL PROPERTY DEPARTMENT
One Liberty Place
1650 Market Street, Suite 4900
Philadelphia, PA 19103

RECEIVED
CENTRAL FAX CENTER
SEP 01 2005

TELEPHONE (215) 656-3300
FACSIMILE (215) 656-2498 OR (215) 656-2499
PROCOMM PLUS (215) 656-2497

FACSIMILE TRANSMITTAL

Attention: Mr. Tony Caputo
Company: USPTO
Facsimile No.: 1-571-273-8300
From: Carol Coney
Date: September 1, 2005
Re: Status on Application
Docket No.: 1105-R-00

Number of Pages (including cover page):

If you do not receive all the pages or experience any difficulty receiving this transmission, please call (215) 656-2412

Additional Instructions/Comments:

As discussed on the phone today, here are the copies you requested. Please let me know the status of the application.

Thank you.

Direct Dial 215-656-2412 and fax 215-656-2498 or 2499

BEST AVAILABLE COPY

BEST AVAILABLE COPY

U.S. Serial No. 09/852,378 filed 5/10/01 for Michael Lazdunski et al. entitled
POLYPEPTIDE INHIBITING A PROTON-GATED Na⁺ CHANNEL, A NUCLEIC ACID
CODING FOR SUCH POLYPEPTIDE AND A METHOD OF MANUFACTURING AN
ASIC1a CHANNEL BLOCKER

Dated: May 22, 2003

Docket: 1105-R-00

Commissioner for Patents

U.S. Serial No. 09/852,378 filed 5/10/01 for Michael Lazdunski et al. entitled
POLYPEPTIDE INHIBITING A PROTON-GATED Na⁺ CHANNEL, A NUCLEIC ACID
CODING FOR SUCH POLYPEPTIDE AND A METHOD OF MANUFACTURING AN
ASIC1a CHANNEL BLOCKER


Dated: May 22, 2003

Docket: 1105-R-00

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450



Sir: Kindly date stamp this card and return it to the undersigned to evidence receipt of
the enclosed Certificate of Mailing, Request To Withdraw Holding Of Abandonment,
Copy of Communication and postcard dated October 14, 2003. Thank you.

T. Daniel Christenbury

:cc

RECEIVED

MAY 27 2003

IP DEPT.

SEP. 1. 2005 1:42PM

DLA PIPER

RECEIVED
CENTRAL FAX CENTER

NO. 941 P. 3

SEP 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1196
Examiner : Michael D. Pak
Serial No. : 09/852,378
Filed : May 10, 2001
Inventors : Michael Lazdunski
: Pierre Escoubas
: Jan De Weille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING A
: PROTON-GATED Na⁺ CHANNEL,
: A NUCLEIC ACID CODING FOR
: SUCH POLYPEPTIDE AND A METHOD
: OF MANUFACTURING AN ASIC^{1a}
: CHANNEL BLOCKER



35811

PATENT TRADEMARK OFFICE

Confirmation No.: 5427

Docket No.: 1105-R-00

Dated: May 20, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Mailing Under 37 CFR 1.8

For

Postcard

Request To Withdraw Holding Of Abandonment
Copy of postcard dated October 14, 2003
Copy of Communication dated October 14, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Piper Rudnick LLP
Customer No. 035811

By:

Date:

Pz
20 MAY 2003

BEST AVAILABLE COPY

U.S. Serial No. 09/825,378 filed 5/10/01 for Michel Lazdunski et al. entitled: POLYPEPTIDE INHIBITING A PROTON-GATED Na⁺ CHANNEL, A NUCLEIC ACID CODING FOR SUCH POLYPEPTIDE AND A METHOD OF MANUFACTURING AN ASIC1a CHANNEL BLOCKER

dated: October 14, 2002

Docket: 1105-R-00

Box Sequence Listing
U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202



RECEIVED

OCT. 24 2002

SHSL
IP DEPT.

ir: Kindly date stamp this card and return it to the undersigned to evidence receipt of the enclosed Certificate of Mailing, Transmittal Letter, Copy of Notice to Comply with requirements for Patent Applications, Substitute Sequence Listing, --Computer readable copy and a printed copy of the Sequence Listing and Statement to Support Filing and submission in accordance with 37 C.F.R. §§ 1.821-1.825. Thank you.

Daniel Christenbury

gj

SEP 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/852378 *pf*
Serial No. : ~~09/825,378~~
Filed : May 10, 2001
Inventors : Michel Lazdumski



22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER

Confirmation No.: 5427

Date: October 14, 2002

Box Sequence Listing
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:

Certificate of Mailing Under 37 CFR 1.8

For
Postcard
Transmittal Letter

Copy of Notice to Comply with Requirements for Patents ... Sequence Disclosures
Computer readable copy and a printed copy of Substitute Sequence Listing
Substitute Statement to Support Filing and Submission in accordance
with 37 C.F.R. §§ 1.821-8.825

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Box Sequence Listing, U. S. Patent and Trademark Office, P. O. Box 2327, Arlington, VA 22202, on the date appearing below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

Schnader Harrison Segal & Lewis
Customer No. 022469

By: *RS*Date: 14 Oct 2002

910013_1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/82378 PF
Serial No. : 09/825,378
Filed : May 10, 2001
Inventors : Michel Lazdunski
: Pierre Escoubas
: Jan DeWeille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER

**22469**

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

Dated: October 14, 2002

TRANSMITTAL LETTER

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:

We acknowledge receipt of the Notice to Comply with Requirements for Patent Applications...dated October 2, 2002, copy enclosed. We submit herewith a computer readable copy and a printed copy of the Substitute Sequence Listing and thereby fulfill the requirements of 37 C.F.R. §§ 1.821-1.825. Also enclosed is a Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825.

Respectfully submitted,

T. Daniel Christenbury
Reg. No. 31,750

TDC:gj
(215) 563-1810

SEP 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1196
Examiner : Michael D. Pak
Serial No. : 09/852,378
Filed : May 10, 2001
Inventors : Michael Lazdunski
: Pierre Escoubas
: Jan De Weille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING A
: PROTON-GATED Na⁺ CHANNEL,
: A NUCLEIC ACID CODING FOR
: SUCH POLYPEPTIDE AND A METHOD
: OF MANUFACTURING AN ASIC1a
: CHANNEL BLOCKER



35811

PATENT TRADEMARK OFFICE

Confirmation No.: 5427

Docket No.: 1105-R-00

Dated: May 20, 2003

REQUEST TO WITHDRAW HOLDING OF ABANDONMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Abandonment dated May 5, 2003, enclosed are copies of the Communication and post card dated October 14, 2002 and showing receipt by the mailroom on October 16, 2002 which was the response to the Office Action dated October 2, 2002.

We respectfully request that the Notice of Abandonment be rescinded.

If any fees are required, please charge our Deposit Account No. 50-1442.

Respectfully submitted,

T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC:cc
(215) 656-3300

SEP 01 2005
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/852 378 PF
Serial No. : 09/825,378
Filed : May 10, 2001
Inventors : Michel Lazdunski
: Pierre Escoubas
: Jan DeWeille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER



22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§1.821-1.825**

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:

In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The submission filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
3. All statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements

910013_1

were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicant
Schnader Harrison Segal & Lewis LLP
1600 Market Street, Suite 3600
Philadelphia, PA 19103-7213

Date: October 14, 2002
TDC:gj
(215) 563-1810

910013_1

Application No.: 09/852,378**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Brief description of drawings for figure 1 discloses sequences which is not identified by SEQ ID NO:.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

U.S. Serial No. 09/825,378 filed 5/10/01 for Michel Lazdunski et al. entitled POLYPEPTIDE INHIBITING A PROTON-GATED Na⁺ CHANNEL, A NUCLEIC ACID CODING FOR SUCH POLYPEPTIDE AND A METHOD OF MANUFACTURING AN ASIC1a CHANNEL BLOCKER

Dated: October 14, 2002

Docket: 1105-R-00

Box Sequence Listing

U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir: Kindly date stamp this card and return it to the undersigned to evidence receipt of the enclosed Certificate of Mailing, Transmittal Letter, Copy of Notice to Comply with Requirements for Patent Applications, Substitute Sequence Listing, —Computer readable copy and a printed copy of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825. Thank you.


U.S. Serial No. 09/825,378 filed 5/10/01 for Michel Lazdunski et al. entitled POLYPEPTIDE INHIBITING A PROTON-GATED Na⁺ CHANNEL, A NUCLEIC ACID CODING FOR SUCH POLYPEPTIDE AND A METHOD OF MANUFACTURING AN ASIC1a CHANNEL BLOCKER

Dated: October 14, 2002

Docket: 1105-R-00

Box Sequence Listing

U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202



RECEIVED

OCT 24 2002

SHSL
IP DEPT.

Sir: Kindly date stamp this card and return it to the undersigned to evidence receipt of the enclosed Certificate of Mailing, Transmittal Letter, Copy of Notice to Comply with Requirements for Patent Applications, Substitute Sequence Listing, —Computer readable copy and a printed copy of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825. Thank you.

T. Daniel Christenbury

DLA PIPER

RECEIVED
CENTRAL FAX CENTER NO. 941

NO. 941 P. 12

SEP 01 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/852378 *HF*
Serial No. : 09/825,378
Filed : May 10, 2001
Inventors : Michel Lazdunski
: Pierre Escoubas
: Jan DeWeille
: Sylvie Dioclot

Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺ Co
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER



22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

Date: October 14, 2002

Box Sequence Listing

U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir,

Certificate of Mailing Under 37 CFR 1.8

**For
Postcard
Transmittal Letter**

Copy of Notice to Comply with Requirements for Patents ...Sequence Disclosures
Computer readable copy and a printed copy of Substitute Sequence Listing
Substitute Statement to Support Filing and Submission in accordance
with 37 C.F.R. §§ 1.821-8.825

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Box Sequence Listing, U. S. Patent and Trademark Office, P. O. Box 2327, Arlington, VA 22202, on the date appearing below.

**Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:**

Schnader Harrison Segal & Lewis
Customer No. 022469

By:

Date:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/852 378 *pf*
Serial No. : ~~09/825,378~~
Filed : May 10, 2001
Inventors : Michel Lazdunski
: Pierre Escoubas
: Jan DeWeille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER



22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

Dated: October 14, 2002

TRANSMITTAL LETTER

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:

We acknowledge receipt of the Notice to Comply with Requirements for Patent Applications...dated October 2, 2002, copy enclosed. We submit herewith a computer readable copy and a printed copy of the Substitute Sequence Listing and thereby fulfill the requirements of 37 C.F.R. §§ 1.821-1.825. Also enclosed is a Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825.

Respectfully submitted,

T. Daniel Christenbury
Reg. No. 31,750

TDC:gj
(215) 563-1810

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1646
Examiner : 09/852378 *rf*
Serial No. : 09/825,378
Filed : May 10, 2001
Inventors : Michel Lazdunski
: Pierre Escoubas
: Jan DeWeille
: Sylvie Diochot
Title : POLYPEPTIDE INHIBITING
: A PROTON-GATED Na⁺
: CHANNEL, A NUCLEIC ACID
: CODING FOR SUCH POLYPEPTIDE
: AND A METHOD OF MANUFACTURING
: AN ASIC1a CHANNEL BLOCKER



22469

PATENT TRADEMARK OFFICE

Docket No.: 1105-R-00

Confirmation No.: 5427

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§1.821-1.825

Box Sequence
U. S. Patent and Trademark Office
P. O. Box 2327
Arlington, VA 22202

Sir:

In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The submission filed in accordance with 37 C.F.R. § 1.821(g), does not include new matter;
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same; and
3. All statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements

were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicant
Schnader Harrison Segal & Lewis LLP
1600 Market Street, Suite 3600
Philadelphia, PA 19103-7213

Date: October 14, 2002
TDC:gj
(215) 563-1810

910013_1

Application No.: 09/852,378

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: Brief description of drawings for figure 1 discloses sequences which is not identified by SEQ ID NO:.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

SEQUENCE LISTING

<110> LAZDUNSKI, MICHEL
ESCOUBAS, PIERRE
DE WEILLE, JAN
DIOCHOT, SYLVIE

<120> POLYPEPTIDE INHIBITING A PROTON-GATED NA + CHANNEL, A
NUCLEIC ACID CODING FOR SUCH POLYPEPTIDE AND A METHOD
OF MANUFACTURING AN ASICIA CHANNEL BLOCKER

<130> 1105-R-00

<140> 09/852,378

<141> 2001-05-10

<150> 60/203,309

<151> 2000-05-10

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 40

<212> PRT

<213> Psalmopoeus sp.

<400> 1

Glu Asp Cys Ile Pro Lys Trp Lys Gly Cys Val Asn Arg His Gly Asp
1 5 10 15

Cys Cys Glu Gly Leu Glu Cys Trp Lys Arg Arg Arg Ser Phe Glu Val
20 25 30

Cys Val Pro Lys Thr Pro Lys Thr
35 40

<210> 2

<211> 36

<212> PRT

<213> Psalmopoeus sp.

<220>

<221> MOD RES

<222> (31)

<223> Variable amino acid

<400> 2

Glu Asp Cys Ile Pro Lys Trp Lys Gly Cys Val Asn Arg His Gly Asp
1 5 10 15

Cys Cys Glu Gly Leu Glu Cys Trp Lys Arg Arg Arg Ser Phe Xaa Val
20 25 30

Cys Val Pro Lys

35

<210> 3
<211> 16
<212> PRT
<213> Psalmopoeus sp.

<400> 3
Lys Arg Arg Arg Ser Phe Glu Val Cys Val Pro Lys Thr Pro Lys Thr
1 5 10 15

<210> 4
<211> 7
<212> PRT
<213> Psalmopoeus sp.

<220>
<221> MOD_RES
<222> (1)..(2)
<223> Variable amino acid

<400> 4
Xaa Xaa Glu Val Cys Val Pro
1 5

<210> 5
<211> 9
<212> PRT
<213> Psalmopoeus sp.

<400> 5
Val Cys Val Pro Lys Thr Pro Lys Thr
1 5

<210> 6
<211> 30
<212> PRT
<213> Psalmopoeus sp.

<400> 6
Asp Asp Cys Gly Lys Leu Phe Ser Gly Cys Asp Thr Asn Ala Asp Cys
1 5 10 15

Cys Glu Gly Tyr Val Cys Arg Leu Trp Cys Lys Leu Asp Trp
20 25 30

<210> 7
<211> 35
<212> PRT
<213> Psalmopoeus sp.

<400> 7

Glu Cys Arg Tyr Leu Phe Gly Gly Cys Lys Thr Thr Ser Asp Cys Cys
 1 5 10 15

Lys His Leu Gly Cys Lys Phe Arg Asp Lys Tyr Cys Ala Trp Asp Phe
 20 25 30

Thr Phe Ser
 35

<210> 8

<211> 41

<212> PRT

<213> Psalmopoeus sp.

<400> 8

Gly Val Asp Lys Ala Gly Cys Arg Tyr Met Phe Gly Gly Cys Ser Val
 1 5 10 15

Asn Asp Asp Cys Cys Pro Arg Leu Gly Cys His Ser Leu Phe Ser Tyr
 20 25 30

Cys Ala Trp Asp Leu Thr Phe Ser Asp
 35 40

<210> 9

<211> 36

<212> PRT

<213> Psalmopoeus sp.

<400> 9

Asp Cys Val Arg Phe Trp Gly Lys Cys Ser Gln Thr Ser Asp Cys Cys
 1 5 10 15

Pro His Leu Ala Cys Lys Ser Lys Trp Pro Arg Asn Ile Cys Val Trp
 20 25 30

Asp Gly Ser Val
 35

<210> 10

<211> 29

<212> PRT

<213> Psalmopoeus sp.

<400> 10

Tyr Cys Gln Lys Trp Met Trp Thr Cys Asp Ser Ala Arg Lys Cys Cys
 1 5 10 15

Glu Gly Leu Val Cys Arg Leu Trp Cys Lys Lys Ile Ile
 20 25

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.